Thermo Fisher Scientific Acquisition Augments Specialty Diagnostics Portfolio
|
By LabMedica International staff writers Posted on 08 Sep 2009 |
|
Thermo Fisher Scientific Inc. (Waltham, MA, USA) signed a definitive agreement to acquire B.R.A.H.M.S. AG (Hennigsdorf, Germany) for US$478.8 million. B.R.A.H.M.S. will be integrated into the specialty diagnostics business within Thermo Fisher's analytical technologies segment. The transaction, which is subject to regulatory approvals, is expected to close in late September 2009.
B.R.A.H.M.S. is a provider of specialty in vitro diagnostic (IVD) tests based on biomarkers for sepsis, cardiovascular and pulmonary diseases, intensive care treatments, and prenatal screening. It also offers diagnostic tests and instrumentation for thyroid, prenatal, autoimmune, and oncology screening in both laboratory and point-of-care settings. The company's best-known product is Procalcitonin (PCT), a biomarker for the diagnosis and treatment of sepsis, a condition in which the patient's bloodstream is overwhelmed by bacterial infection.
The PCT test has become the gold standard in Europe for early diagnosis of sepsis, which is critical for patient survival, and the subsequent monitoring of treatment. The European testing model will be replicated in the United States where around 750,000 cases occur each year, one third of which are fatal.
Marijn E. Dekkers, president and CEO of Thermo Fisher Scientific, commented, "B.R.A.H.M.S. assays and instrumentation are a strong complement to our existing products for immunoassay testing, and its robust R&D pipeline creates promising opportunities to commercialize new patented diagnostic tests. In addition, the company gives us a significant reagent manufacturing footprint in Europe, while allowing us to leverage our deep customer access in the U.S. to market innovative new B.R.A.H.M.S. products, such as PCT and others now in development. This acquisition reinforces our strategy of building on our leadership in niche specialty diagnostics markets.”
Thermo Fisher Scientific Inc. supplies and serves hospitals and clinical diagnostic labs, pharmaceutic and biotechnology companies, universities, research institutions and government agencies, as well as environmental and industrial process control settings. The company has two brands, Thermo Scientific and Fisher Scientific. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.
Related Links:
Thermo Fisher Scientific Inc.
B.R.A.H.M.S. AG
B.R.A.H.M.S. is a provider of specialty in vitro diagnostic (IVD) tests based on biomarkers for sepsis, cardiovascular and pulmonary diseases, intensive care treatments, and prenatal screening. It also offers diagnostic tests and instrumentation for thyroid, prenatal, autoimmune, and oncology screening in both laboratory and point-of-care settings. The company's best-known product is Procalcitonin (PCT), a biomarker for the diagnosis and treatment of sepsis, a condition in which the patient's bloodstream is overwhelmed by bacterial infection.
The PCT test has become the gold standard in Europe for early diagnosis of sepsis, which is critical for patient survival, and the subsequent monitoring of treatment. The European testing model will be replicated in the United States where around 750,000 cases occur each year, one third of which are fatal.
Marijn E. Dekkers, president and CEO of Thermo Fisher Scientific, commented, "B.R.A.H.M.S. assays and instrumentation are a strong complement to our existing products for immunoassay testing, and its robust R&D pipeline creates promising opportunities to commercialize new patented diagnostic tests. In addition, the company gives us a significant reagent manufacturing footprint in Europe, while allowing us to leverage our deep customer access in the U.S. to market innovative new B.R.A.H.M.S. products, such as PCT and others now in development. This acquisition reinforces our strategy of building on our leadership in niche specialty diagnostics markets.”
Thermo Fisher Scientific Inc. supplies and serves hospitals and clinical diagnostic labs, pharmaceutic and biotechnology companies, universities, research institutions and government agencies, as well as environmental and industrial process control settings. The company has two brands, Thermo Scientific and Fisher Scientific. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables, and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies, and services used in healthcare, scientific research, safety, and education.
Related Links:
Thermo Fisher Scientific Inc.
B.R.A.H.M.S. AG
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Automated Urinalysis Solution
UN-9000
Latest Industry News
- New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies
- New Collaboration Advances Precision Oncology Screening for Lung Cancer in Japan
- AI-Powered Pathology Collaboration Supports Companion Diagnostic Development
- Strategic Collaboration Expands Commercial Access to Oncology Companion Diagnostics
- Collaboration Supports Global ADC Development with AI-Powered Tissue Analysis
- Standardized Staining Technology Advances Digital Pathology Workflows
- Global Testing Service Advances Leukemia MRD Monitoring
- Ultrasensitive MRD Assay Gains Medicare Coverage for Immunotherapy and Breast Cancer Monitoring
- Genprex and Roche Collaborate on AI-Driven NSCLC Biomarker Testing
- Collaboration Explores Clinical Use of Single-Cell and Spatial Technologies
- Partnership Brings Automated Pathology Archiving Solutions to U.S. Labs
- New Collaboration Integrates Low-Code Automation into Laboratory Platform
- LumiQuick Advances Oxidative Stress Research with Expanded AOXRE Portfolio
- Collaboration Advances Extracellular Vesicle-Based Tests for Neurodegenerative Diseases
- Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
- Tempus to Acquire Personalis in $1.5 Billion Precision Oncology Deal
Channels
Clinical Chemistry
view channel
Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease
Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more
Blood Test Markers Could Help Identify Older Adults at Risk of Disability
Maintaining independence into very old age is a growing public health challenge as Japan’s population rapidly ages. Nearly 60% of Japanese adults aged 85 years and older already receive support through... Read more
Molecular Diagnostics
view channel
New Liquid Biopsy Approach Shows Promise for Detecting Breast Cancer Recurrence
Many liquid biopsy strategies for monitoring breast cancer recurrence focus on detecting genetic mutations in tumor DNA. Researchers are evaluating whether additional features of circulating cell-free... Read more
Whole-Blood RNA Test Could Improve Breast Cancer Screening in Dense Breasts
Breast cancer screening continues to face challenges, including limited detection of small tumors and uneven participation, particularly among women with dense breasts. These limitations can leave diagnostic... Read more
Hematology
view channel
New Genetic Findings Reveal Cause of Bone Marrow Failure Syndrome
Inherited bone marrow failure syndromes (IBMFS) impair the bone marrow’s ability to produce sufficient healthy blood cells and are associated with an increased risk of early-onset myelodysplastic syndromes (MDS).... Read more
Ultra-Portable Device Enables Finger-Prick Blood Testing at Home
Patients who need frequent blood tests often face repeated clinic visits that burden services and disrupt care. In the UK, millions of tests are performed each year to diagnose disease, guide therapy,... Read more
Immunology
view channel
AI-Based Antibody Profiling Predicts Strength of COVID-19 Vaccine Response
Vaccine-induced protection can vary widely between individuals, creating uncertainty for clinicians, particularly in patients with immunosuppressive conditions. Demographic and health factors explain only... Read more
Immune Biomarkers May Predict Recurrent Checkpoint Inhibitor Arthritis
Inflammatory arthritis is a recognized immune-related adverse event in patients treated with immune checkpoint inhibitors (ICIs) for cancer. Between 20% and 50% of affected patients experience more than... Read more
Microbiology
view channel
Genetic Marker Identifies Emerging Resistance to Frontline Malaria Drugs
Artemisinin-based combination therapy remains central to controlling Plasmodium falciparum malaria, but emerging drug resistance is complicating treatment and surveillance. In Uganda and across sub-Saharan... Read more
Surveillance and Susceptibility Testing Track Rising Candida Auris in U.S.
Drug-resistant fungal infections are straining infection control and treatment in hospitals and long-term care facilities, where rapid transmission can lead to severe outcomes. Candida auris has expanded... Read more
Pathology
view channel
AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis
Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more
New Review Highlights Intelligent Agents as Next Step for Digital Pathology
Digital pathology remains constrained by models that classify single images without mirroring how clinicians interrogate multiple slides, adjust magnification, and synthesize ancillary tests.... Read more
Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism
Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Technology
view channel
Autonomous Robotic System Receives FDA Authorization for Blood Collection
Venipuncture is central to many diagnostic pathways, but routine blood collection can be affected by staffing constraints and procedural variability that influence consistency and patient experience.... Read more
